Dosing is personalized based on individual tolerance and health goals
Glutathione often gives quicker, more visible skin results
Evidence Boundary Most studied route in the Phase 2 program, but the OPTIONS trial missed its primary weight-loss endpoint and development was terminated in 2007
Setria Glutathione + Liposomal: the combination that overcomes the absorption bottleneck Two challenges need solving: Protect glutathione from being broken down in the gut Deliver it in a form your cells can actually take up Setria Glutathione is clinically shown (5a) to raise glutathione inside cells, not just in circulation, solving the does it work once absorbed? problem
A pilot study found that oral administration of GSH (300 mg/day) for 4 months can decrease ALT levels and hepatic steatosis in Japanese NAFLD patients, in those without severe fibrosis or uncontrolled diabetes
This is the adaptation phase, not the results phase